Default company panoramic image

Avisa Pharma Inc

Infections in hospitals are the fourth largest killer in the United States. The Avisa BreathTest technology addresses this huge problem.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Santa Fe, NM, USA
  • Currency USD
  • Employees 2
  • Website avisapharmacom

Company Summary

Avisa Pharma™ Inc. is a clinical stage company developing a proprietary, point-of-care biomarker BreathTest for the rapid and accurate detection and monitoring of patients with Ventilator Associated Pneumonia (VAP) and Cystic Fibrosis (CF) and Tuberculosis (TB). Such multi-drug resistant pathogens compromise lung functionality, morbidity and/mortality. Regulated as a drug/device under a 510k, AV-1 BreathTest is a new use of a marketed product.


  • Default avatar
    Graham S Timmins, Ph.D.
    Chief Science Officer

    Co-founder and Associate Professor, Pharmaceutical Sciences, University of New Mexico. Patented and developed Avisa's stable, non-radioactive isotope technology platform. Recipient of multiple federal grants, over 50 scientific publications.

  • Default avatar
    David S Joseph
    President and CEO

    Co-Founder of Avisa Pharma with 40 years of lifescience experience, co-founder and CEO of four lifescience companies in medical technology, biomaterials and biopharmaceuticals. Successful exits include two public companies and two acquisitions.

  • Default avatar
    Elizabeth A Perkett, MD
    Chief Medical Officer

    Former Professor of Pulmonary Medicine, Vanderbilt University, Cystic Fibrosis specialty. Full time Avisa CMO, over 50 recent clinical publications.


  • Default avatar
    Schuler Daly
    Default avatar
    Stacey Humphrey

Previous Investors

  • Default avatar
    $400,000 raised from current investors in the Convertible Note Seed round.